Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Company Overview - Oncocyte Corp. is a pioneering diagnostics technology company focused on providing clarity and confidence to physicians and their patients [2] - The company offers several diagnostic tests, including VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™, which are designed for solid organ transplantation monitoring and cancer treatment efficacy [2] Conference Participation - Oncocyte's CEO Josh Riggs and CFO Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah on February 11-12, 2025 [1] - The company will host one-on-one meetings with interested investors during the conference [1] Product Information - VitaGraft™ is a clinical blood-based test for solid organ transplantation monitoring [2] - GraftAssure™ is a research use only (RUO) blood-based test for solid organ transplantation monitoring [2] - DetermaIO™ is a gene expression test that evaluates the tumor microenvironment to predict responses to immunotherapies [2] - DetermaCNI™ is a blood-based tool for monitoring therapeutic efficacy in cancer patients [2]